Defining response to anti-VEGF therapies in neovascular AMD

• Published in: Eye (London) Vol. 29; no. 6; pp. 721 - 731
• Main Authors: Amoaku, W M, Chakravarthy, U, Gale, R, Gavin, M, Ghanchi, F, Gibson, J, Harding, S, Johnston, R L, Kelly, S, Lotery, A, Mahmood, S, Menon, G, Sivaprasad, S, Talks, J, Tufail, A, Yang, Y
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2015; Nature Publishing Group
• Subjects: 692/1807; Angiogenesis Inhibitors - therapeutic use; Humans; Intravitreal Injections; Laboratory Medicine; Medicine; Medicine & Public Health; Ophthalmology; Pharmaceutical Sciences/Technology; Practice Guidelines as Topic; Review; Surgery; Surgical Oncology; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - physiopathology

The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant impact on the reduction of the visual loss due to neovascular age-related macular degeneration (n-AMD). There are significant inter-individual differences in response to an anti-VEGF agent, made more complex...